ROFLyou persue that one,mateThe collaboration with UniSyd is a...

ROFL

you persue that one,mate

The collaboration with UniSyd is a first as far as I'm aware for CNN - so unless they have kept certain developments from us I would deem CNN "dipping a toe" into this new biomimetic space (could be very successful though)

A lot of research has been done with a lot of IP already being locked up.

The second you are talking nano-particles and drugs you are looking at doing a full PhIII trial (a and b, multi-centre, multinational) even if the drug used has been previously approved.

From what I can gather CNN/SydUni collaboration is about moving in the medical device space (totally different approval schedule and time frame) and I would guess a fair bit in the "consumable" space within drug delivery.

I see a fair bit of sales value in the "consumable space" that would keep us pretty happy if CNN can move into that !

2013 is shaping up to be a year for bio-techs on quite a few fronts - also some new challenges on how data is released to shareholders (check ANP thread re potential ISIS class action). This could transform this space radically - especially the way and depth data is released to the investor.

Bulk of CNN potential is the fiercely competitive space of packaging/Hygene Liners/containers and new products to be introduced in the coming years.

One step at a time - will do me.